I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 37 studies | 47% ± 16% | |
| CD8-positive, alpha-beta T cell | 21 studies | 26% ± 13% | |
| mature NK T cell | 17 studies | 40% ± 18% | |
| CD16-negative, CD56-bright natural killer cell, human | 15 studies | 54% ± 21% | |
| gamma-delta T cell | 15 studies | 34% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 13 studies | 53% ± 18% | |
| mucosal invariant T cell | 9 studies | 29% ± 8% | |
| CD8-positive, alpha-beta memory T cell | 7 studies | 26% ± 6% | |
| T cell | 6 studies | 25% ± 5% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 6 studies | 22% ± 8% | |
| effector memory CD8-positive, alpha-beta T cell | 6 studies | 33% ± 14% | |
| innate lymphoid cell | 6 studies | 42% ± 18% | |
| glutamatergic neuron | 4 studies | 36% ± 12% | |
| brush cell | 4 studies | 52% ± 17% | |
| mast cell | 3 studies | 22% ± 4% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 3 studies | 28% ± 7% | |
| hematopoietic precursor cell | 3 studies | 24% ± 8% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 28% ± 10% |
